Hormonal
Once-weekly subcutaneous semaglutide 2.4 mg induces greater weight loss from baseline than placebo and once-daily liraglutide 3.0 mg in patients with overweight or obesity, with or without type 2 diabetes.
Semaglutide 2.4 mg is a once-weekly injection approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities. It is taken alongside a calorie-controlled diet and increased physical activity. The dose starts low (0.25 mg) and increases every 4 weeks to 2.4 mg to minimize side effects. It is currently the most efficacious medication for weight loss, producing double-digit percentage body weight reductions over 1-2 years, superior to placebo and once-daily liraglutide.
The phase 3 STEP clinical development program to date has demonstrated that, among patients with overweight and obesity, with and without T2D, once-weekly injectable semaglutide 2.4 mg treatment induces greater weight loss from baseline than placebo (STEP 1–6) and once-daily liraglutide 3.0 mg (STEP 8).
Why this rating
Based on multiple phase 3 randomized, double-blind, placebo- and active-controlled trials (STEP 1-8) involving over 5000 subjects.
Source
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
David C.W. Lau et al. · Expert Review of Clinical Pharmacology · 2022
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →